GlassScriptPhysician profile
Vijay Juneja
NPI 1851388912
$3,449.32
in general payments reported to CMS, 2019-2025
30 companies · $593 in 2025
The $593 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $265 · 2021: $426 · 2022: $614 · 2023: $366 · 2024: $519 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391 · Education: $87.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.78 |
| Education | $87.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $740.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $353.64 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $293.88 | 2020-2024 | Eliquis, Camzyos |
| Abbvie INC. | $230.22 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.50 | 2019-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $193.06 | 2019-2023 | Belsomra |
| Astrazeneca Pharmaceuticals LP | $159.16 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $151.00 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $128.74 | 2019-2025 | |
| Abbott Laboratories | $121.41 | 2022-2025 | Eterna, Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $115.46 | 2019-2025 | |
| Mannkind Corporation | $97.31 | 2021-2025 | |
| Amarin Pharma, INC. | $80.98 | 2019-2021 | |
| Insulet Corporation | $70.51 | 2021-2025 | Omnipod |
| Dexcom, INC. | $67.31 | 2021-2025 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $50.93 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $49.38 | 2019-2022 | |
| Eisai INC. | $38.05 | 2024 | |
| Allergan, INC. | $32.37 | 2019-2020 | |
| Beta Bionics, INC. | $32.27 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Organogenesis INC. | $30.00 | 2025 | Apligraf |
| Medtronic, INC. | $29.33 | 2021-2025 | Minimed 780g |
| Glaxosmithkline, LLC. | $22.45 | 2023 | Shingrix, Arexvy |
| Vifor Pharma, INC. | $22.00 | 2024 | Veltassa |
| Phathom Pharmaceuticals, INC. | $19.78 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $19.51 | 2024 | |
| Medtronic Minimed, INC. | $18.94 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.05 | 2024 | Xifaxan |
| Exact Sciences Corporation | $17.13 | 2024 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $16.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Juneja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.